Author Archives: Best Practices
When Personal and Professional Experiences Meet, Our Clients Benefit: Part 4 of New Series
Let’s be real, 2020 has been a hard year. It’s hard to know what to do or what not to do; it’s hard to navigate business decisions, when it’s NOT business as usual. We want you to know that while
When Personal and Professional Experiences Meet, Our Clients Benefit: Part 3 of New Series
Let’s be real, 2020 has been a difficult year thus far. We see people hunkering down, their focus shifting and some reticence to make decisions. Best Practices has felt these seismic shifts as well, but one thing that has not
When Personal and Professional Experiences Meet, Our Clients Benefit: Part 2 of New Series
2020 has been a difficult year, but the need for speed in making business decision is becoming more critical. Best Practices recognizes that seismic shifts in how business is conducted are facing all companies, and we want to re-confirm our
When Personal and Professional Experiences Meet, Our Clients Benefit: Part 1 of New Series
Let’s be real, 2020 has been a hard year for most of us. It’s hard to know what to do or what not to do; it’s hard to navigate business decisions, when it’s NOT business as usual. We see people
Relationships Matter: To be Effective, Medical Information Groups in Pharmaceutical Companies Must Forge Collaborative Relationships with other Internal Groups such as Legal
Within the pharmaceutical sector, medical information groups shoulder great responsibilities. The principal role of medical information groups, which are typically part of the medical affairs organization, is responding to questions about products from external groups such as physicians. While this
Best Practices Hosts 7th Digital Marketing Consortium Roundtable
Best Practices hosted our 7th Digital Marketing Consortium Roundtable on Thursday, July 23. The topic of the virtual conference was “Key Trends & Innovative Activities in 2015 Biopharma Digital Marketing.” The roundtable brought together executives from 8 leading pharmaceutical companies
Best Practices Hosting 6th Medical Affairs Consortium on HEOR
Best Practices will be hosting the sixth roundtable of our Medical Affairs Consortium on Thursday (May 28th) from 11:00AM-12:30PM (EST) via a virtual roundtable to discuss “Medical Affairs’ Role in Health Economics & Outcomes Research.” This is the final roundtable
Exclusive: Key Findings from Best Practices’ 5th Medical Affairs Consortium
Best Practices recently completed the second roundtable of our 2014-2015 Medical Affairs Consortium. The roundtable addressed the topic of “Medical Affairs Launch Support.” The roundtable brought together executives from 13 leading pharmaceutical organizations. Some exclusive key findings from the discussion
Top Trends in 2015 – Is Your Organization Prepared?
2015 is here & with the New Year comes many new trends and topics of discussion. With the increasing importance of payers and high demand on evidence-based information, it is clear that there are many shifts happening in the pharmaceutical,
Best Practices in Lifecycle Management: Maximizing the Potential of Mature Brands
As many drugs are reaching the patent cliff, strategies to extend the commercial life of mature brands is critical to today’s pharmaceutical industry. Used correctly, lifecycle management strategies can add as many as 10 years and billions of dollars to
Medical Affairs Consortium: Impact Measures, Globalization & Compliance
On November 6, 2014 Best Practices, LLC hosted the 1st roundtable of the 2014-2015 Medical Affairs’ Consortium. The roundtable brought together leaders from: Baxter, Crescendo, Eli Lilly, Genentech, Incyte Corporation, Jazz Pharmaceuticals, Pfizer, Santen Inc., Teva, and Upsher-Smith. Leaders from
Best Practices’ Hosting Medical Affairs Consortium Roundtable Thursday, Nov. 6
Best Practices designed the Medical Affairs Consortium to provide Medical Affairs leaders with a forum for sharing insights about the key challenges they face. The consortium has developed a mechanism for creating and sharing solutions through three virtual roundtable discussions
Pharma Companies Feeling the Heat From the Sunshine Act
Last week marked the release of the initial data from the Sunshine Act law of the Affordable Care Act, which had been dreaded by many health care professionals and pharmaceutical and medical device executives. So, for the past few years,